Allied Market Research

2024

Dendritic Cell Cancer Vaccines Market

Dendritic Cell Cancer Vaccines Market Size, Share, Competitive Landscape and Trend Analysis Report, by Product Type and, by End User : Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Pharmaceuticals

Select an option
Author's: | Roshan Deshmukh
Publish Date:

Get Sample to Email

Dendritic cells (DCs) refer to rare kind of leukocytes. They have prompted their recent application to therapeutic cancer vaccinations as they are uniquely effective in their ability to present antigens to T cells. Isolated DCs loaded with tumor antigen ex vivo and administered as a cellular vaccine are found to induce protective and therapeutic anti-tumor immunity in experimental animals. Increase in prevalence of cancer, improvement of technology such as drug innovations regarding cancer, upsurge in awareness about cancer and their available therapies in the market, and increase in health care expenditure drive the market. In contrast, low accessibility to vaccines in remote areas and stringent regulatory procedures restrain the market.

This report segments the global dendritic cell cancer vaccine market based on type, end user, and region. Based on type, it is categorized into CreaVax, Sipuleucel-T (Provenge), and others. Based on end user, it is classified into pediatrics, and adults. By geography, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
The key players of the dendritic cell cancer vaccine market are 3M Company, Activarti, Argos Therapeutics, Batavia Bioservices, Bellicum Pharmaceuticals, Creagene, DanDrit Biotech, DCPrime, Sanpower Corporation (Dendreon Corporation), Elios Therapeutics. ImmunoCellular Therapeutics, Immunicum, Kiromic, Medigene, Merck & co, Northwest Biotherapeutics, Glaxo Smith Kline, ImmunoCellular Therapeutics, Tella Incorporation, and Vaxil BioTherapeutics.

Key Benefits

  • The study provides an in-depth analysis of the global dendritic cells cancer vaccine market, with current trends and future estimations to elucidate the imminent investment pockets.
  • It presents a quantitative analysis¬†to enable the stakeholders to capitalize on prevailing market opportunities.
  • Extensive analysis of the market by product type assists in understanding the various forms of dendritic cells cancer vaccine available.
  • Key players are profiled and their strategies are analyzed thoroughly, which predict the competitive outlook of the market.

Dendritic Cell Cancer Vaccines Market Report Highlights

Aspects Details
icon_5
By Product Type
  • CreaVax
  • Sipuleucel-T (Provenge)
  • Others
icon_6
By End User
  • Pediatrics
  • Adults
icon_7
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
icon_8
Key Market Players

ImmunoCellular Therapeutics, DanDrit Biotech, Creagene, Argos Therapeutics, Medigene, Immunicum, Northwest Biotherapeutics, Vaxil BioTherapeutics, 3M Company, Bellicum Pharmaceuticals, Glaxo Smith Kline, Batavia Bioservices, Activarti, DCPrime, Sanpower Corporation (Dendreon Corporation), Merck & Co., Tella Incorporation, Kiromic, Elios Therapeutics

Loading Table Of Content...

Individual sections of the reports are available for purchase.
Would you like to see a breakdown of prices by section?

Dendritic Cell Cancer Vaccines Market

Global Opportunity Analysis and Industry Forecast, 2023-2032